Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -0.71%5 Net Margin % is -79,155.56% as of Dec. 2025. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,832 Software companies, Vitrafy Life Sciences ranks worse than 99.26% on this metric.
The historical rank and industry rank for Vitrafy Life Sciences's Net Margin % or its related term are showing as below:
ASX:VFY'
s Net Margin % Range Over the Past 10 Years
Min: -50323.08 Med: -28175.68 Max: -21440.91
Current: -21440.91
ASX:VFY's Net Margin % is ranked worse than 99.26% of 2832
companies
in the Software industry
Industry Median: 2.61
vs ASX:VFY: -21440.91
Vitrafy Life Sciences (ASX:VFY) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vitrafy Life Sciences Net Margin % Related Terms
Vitrafy Life Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Vitrafy Life Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, ORCL, PLTR: Net Margin % Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences Net Margin % vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a Net Margin % of -79,155.56% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #2811 out of 2832 companies in the Software industry, placing it in the top 99.3%.
Is Vitrafy Life Sciences' Net Margin % too high?
Vitrafy Life Sciences' current Net Margin % is -79,155.56%. Based on the distribution chart, Vitrafy Life Sciences ranks #2811 out of 2832 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' Net Margin % compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #2811 out of 2832 companies for Net Margin %. This places Vitrafy Life Sciences in the lower half of its industry. The industry median Net Margin % is 2.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Software company?
The median Net Margin % among Software companies is 2.61, based on 2,832 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median Net Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current Net Margin % is -79,155.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current Net Margin % of -79,155.56%. The current Net Margin % is -79,155.56%. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current Net Margin % is -79,155.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
